In a regulatory filing, the company states: “On October 31, 2024, ADMA Biologics (ADMA) and KPMG LLP executed an agreement pursuant to which KPMG will initiate its engagement and serve as the Company’s new independent registered public accounting firm effective upon the filing of the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2024. KPMG’s engagement will include an audit of Company’s consolidated financial statements for the fiscal year ending December 31, 2024, which will be filed as part of the Company’s Annual Report on Form 10-K anticipated to be filed on or before March 3, 2025.”
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADMA:
- Adma Biologics selloff brings attractive entry point, says Mizuho
- ADMA Biologics Confirms Auditor Change Won’t Affect Projections
- Adma Biologics to join S&P SmallCap 600 Index
- Biotech Alert: Searches spiking for these stocks today
- S&P announces changes to S&P 400, 600 indexes for quarterly rebalance